Aurinia Pharmaceuticals (AUPH) Cash & Equivalents (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Cash & Equivalents data on file, last reported at $41.0 million in Q1 2026.

• Quarterly Cash & Equivalents fell 38.27% year-over-year to $41.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.0 million (down 38.27% YoY) and the FY2025 annual result came in at $80.2 million, down 3.86% from the prior year.
• Cash & Equivalents declined to $41.0 million in Q1 2026, from $80.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $151.6 million in Q2 2022 to a low of $33.4 million in Q2 2024.
• A 5-year average of $74.3 million and a median of $73.2 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 59.39% — and 2025, when it jumped 97.05%.
• Tracing AUPH's Cash & Equivalents over 5 years: stood at $94.2 million in 2022, then slumped by 48.1% to $48.9 million in 2023, then surged by 70.71% to $83.4 million in 2024, then declined by 3.86% to $80.2 million in 2025, then sank by 48.88% to $41.0 million in 2026.
• The last three Cash & Equivalents figures came in at $41.0 million (Q1 2026), $80.2 million (Q4 2025), and $73.2 million (Q3 2025), per Business Quant data.